TSS
TVRD

Two Sigma Securities’s Tvardi Therapeutics TVRD Stock Holding History

Two Sigma Securities’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-305
Closed -$9.99K – 3812
2024
Q1 		$9.99K Sell
305
-53
-15% -$1.37K ﹤0.01% 2766
2023
Q4 		$9.57K Buy
+358
New +$14.8K ﹤0.01% 2822
2023
Q3 		– Sell
-669
Closed -$68.2K – 3585
2023
Q2 		$68.2K Buy
669
+340
+103% +$46.8K ﹤0.01% 2361
2023
Q1 		$58.2K Buy
+329
New +$110K ﹤0.01% 2266
2017
Q3 		– Sell
-307
Closed -$170K – 1269
2017
Q2 		$170K Sell
307
-73
-19% -$46.3K 0.03% 594
2017
Q1 		$252K Buy
+380
New +$203K 0.05% 475

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Securities's TVRD Position: Q2 2024 in Review

Two Sigma Securities sold out of Tvardi Therapeutics (TVRD) in Q2 2024, closing a stake of 305 shares — an estimated $9.99K sold.

Two Sigma Securities first reported a position in TVRD in Q1 2017 and held it in 6 quarters. The position peaked at $252K in Q1 2017. 79 funds tracked by Wall St. Rank hold TVRD as of Q2 2024.

  • Two Sigma Securities reported no remaining Tvardi Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Two Sigma Securities sold 305 Tvardi Therapeutics shares in Q2 2024, an estimated $9.99K.
  • Two Sigma Securities first reported a position in Tvardi Therapeutics in Q1 2017 and held it in 6 quarters.
  • Two Sigma Securities's Tvardi Therapeutics position peaked at $252K in Q1 2017.
  • 79 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2024.

Based on Two Sigma Securities's 13F filing for Q2 2024, filed 14 Aug 2024.